Cocrystal Pharma (NASDAQ:COCP) Releases Earnings Results, Beats Expectations By $0.01 EPS

Cocrystal Pharma (NASDAQ:COCP) posted its quarterly earnings data on Tuesday. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.01, FiscalAI reports.

Cocrystal Pharma Stock Up 1.0%

Shares of COCP stock opened at $1.02 on Thursday. The stock has a market cap of $14.06 million, a P/E ratio of -1.29 and a beta of 1.18. The company’s fifty day simple moving average is $1.01 and its two-hundred day simple moving average is $1.06. Cocrystal Pharma has a 52 week low of $0.86 and a 52 week high of $2.67.

Insider Buying and Selling at Cocrystal Pharma

In related news, Director Phillip Md Et Al Frost bought 50,000 shares of the business’s stock in a transaction dated Friday, February 6th. The shares were purchased at an average price of $0.95 per share, with a total value of $47,500.00. Following the transaction, the director owned 1,888,551 shares in the company, valued at $1,794,123.45. This trade represents a 2.72% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 28.14% of the stock is currently owned by company insiders.

Institutional Trading of Cocrystal Pharma

An institutional investor recently bought a new position in Cocrystal Pharma stock. DRW Securities LLC bought a new stake in Cocrystal Pharma, Inc. (NASDAQ:COCP) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned approximately 0.24% of Cocrystal Pharma as of its most recent SEC filing. Hedge funds and other institutional investors own 6.72% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cocrystal Pharma in a research report on Monday, December 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Cocrystal Pharma presently has an average rating of “Hold” and a consensus price target of $6.00.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.